According to the company, treatment with SCY-635 was well tolerated and produced a clinically relevant reduction in plasma hepatitis C virus (HCV) RNA.
The clinical study was conducted as a Phase Ib, randomized, double-blind, placebo-controlled, multi-dose study in adult volunteers with genotype 1 chronic hepatitis C infection. SCY-635 was given as an oral capsule for 15 consecutive days. Full results of the study will be announced in 2009.
Yves Ribeill, president and CEO of Scynexis, said: “These data are very encouraging, demonstrating the therapeutic potential of SCY-635 in patients with HCV as well as validating our core discovery platform which is focused on developing cyclophilin inhibitors for multiple diseases, including serious viral diseases, central nervous system disorders and autoimmune diseases.
“Based on these promising results, we are actively planning the clinical and regulatory path forward for the development of SCY-635 and will continue to advance additional novel candidates from the platform for other therapeutic indications.”